Avanos MedicalFRA:8HH 62 EV-to-FCF is 176.94 as of Jul. 09, 2026, which is 1069% above its 10-year median of 15.14. GuruFocus rates FRA:8HH with a GF Score™ of 62/100 and a GF Value™ of €16.66. The stock has 5 warning signs investors should review. Among 416 Medical Devices & Instruments companies, Avanos Medical ranks worse than 90.14% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avanos Medical's Enterprise Value is €1,089.1 Mil.
Avanos Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €6.2 Mil. Therefore, Avanos Medical's EV-to-FCF for today is 176.94.
The historical rank and industry rank for Avanos Medical's EV-to-FCF or its related term are showing as below:
FRA:8HH'
s EV-to-FCF Range Over the Past 10 Years
Min: -365.07 Med: 15.14 Max: 168.36
Current: 165.37
During the past 13 years, the highest EV-to-FCF of Avanos Medical was 168.36. The lowest was -365.07. And the median was 15.14.
FRA:8HH's EV-to-FCF is ranked worse than 90.14% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.515
vs FRA:8HH: 165.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avanos Medical's PE Ratio (TTM) for today is calculated as:
Avanos Medical's share price for today is €21.40.
Avanos Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.396.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avanos Medical EV-to-FCF Related Terms
Avanos Medical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Avanos Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Avanos Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avanos Medical EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avanos Medical's EV-to-FCF falls into.
Avanos Medical's current Enterprise Value is €1,089.1 Mil.
Avanos Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avanos Medical (FRA:8HH) has a EV-to-FCF of 176.94 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avanos Medical and its competitors. This is 1069% above median its historical median of 15.14. According to the industry distribution chart, Avanos Medical ranks #375 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 90.1%.
Is Avanos Medical's EV-to-FCF too high?
Avanos Medical's current EV-to-FCF of 176.94 is 1069% above median its 10-year median of 15.14. The Medical Devices & Instruments industry median EV-to-FCF is 23.52. Avanos Medical's value of 176.94 is 652.5% above this industry median. Based on the distribution chart, Avanos Medical ranks #375 out of 416 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avanos Medical has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's EV-to-FCF compare to LMRI and AORT?
According to the Medical Devices & Instruments industry distribution chart, Avanos Medical ranks #375 out of 416 companies for EV-to-FCF. This places Avanos Medical in the lower half of its industry. The industry median EV-to-FCF is 23.52. Avanos Medical's value of 176.94 is 652.5% above this benchmark. While the company's 10-year median is 15.14 vs. the industry median of 23.52, Avanos Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avanos Medical's current EV-to-FCF of 176.94 is 652.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avanos Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avanos Medical's current EV-to-FCF is 176.94, which is 1069% above median its own 10-year median of 15.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Avanos Medical (FRA:8HH) has a current EV-to-FCF of 176.94. The stock's GF Value™ is €16.66, compared to a current price of €21.40 — trading 28.5% above its estimated fair value. The current EV-to-FCF is 176.94, which is 1069% above median its 10-year median of 15.14 and 652.5% above the Medical Devices & Instruments industry median of 23.52. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Avanos Medical (FRA:8HH), the current EV-to-FCF is 176.94 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avanos Medical (FRA:8HH) Overvalued in 2026?
Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued.
The current stock price of €21.40 is trading 28.5% above its estimated GF Value™ of €16.66.
Key valuation signals for FRA:8HH:
EV-to-FCF: 176.94 (1069% above median its 10-year median of 15.14)
GF Value™: €16.66 vs. price of €21.40 (28.5% above fair value)
Industry Position: 652.5% above the Medical Devices & Instruments median (#375 of 416)
No single metric tells the full story. See the FRA:8HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
62GF Score
Get the complete analysis for FRA:8HH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8HH has been successfully added to your 
